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The use of genomewide ENU
mutagenesis screens to unravel
complex mammalian traits:
identifying genes that regulate organspecific and systemic autoimmunity

Summary: T-cell development is perhaps one of the best understood
processes of mammalian cell differentiation, as many of the genes and
pathways have been identified. By contrast, relatively little is known
about the genes and pathways involved in immunological tolerance to
self-antigens. Here, we describe the challenges associated with a genomewide screen designed at identifying new immune regulatory genes that
uses a model of organ-specific autoimmunity leading to type 1 diabetes.
The successful propagation and identification of the new gene variants
will shed light on the various developmental checkpoints in lymphocyte
development that are crucial for establishing tolerance to self-antigens.

Introduction
The adaptive immune system comprises a large repertoire of
antigen-specific T and B lymphocytes that have the potential
to respond to any microbial pathogen. The immune system is
faced with an enormous task of ensuring that all of the T and
B cells it generates express antigen receptors that have high
affinity for foreign proteins and do not respond to selfproteins. The functional silencing and removal of ‘forbidden’
self-reactive lymphocytes is referred to as immunological
tolerance. Failure of self-tolerance leads to life-threatening
autoimmune diseases.
During their development, immature T and B cells must
negotiate several developmental checkpoints that ensure that
they do not express an antigen receptor with high affinity for
self-antigen that occurs in the thymus for T cells and the bone
marrow for B cells (1). Forbidden self-reactive clones are
instructed to die by apoptosis, and this process is referred to
as clonal deletion. It is understood that more than 95% of
thymocytes fail to progress to the final stages of T-cell maturation. However, not all self-reactive lymphocytes are deleted,
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and a small percentage of forbidden clones escape and enter
the periphery. The fact that <7% of the population develops
autoimmune disease illustrates that the immune system has
developed a number of effective mechanisms to control the
fate of self-reactive lymphocytes (1).
Cellular checkpoints in immunological tolerance
The immune system relies on a range of cell-intrinsic and extrinsic mechanisms to limit the activation and differentiation of self-reactive lymphocytes. The discussion in this
review is focused mostly on the mechanisms related to
T-cell tolerance.
Clonal deletion

Clonal deletion is the primary mechanism used to remove
self-reactive T cells during their development. The T-cell
receptor (TCR) recognizes processed peptides presented in
association with major histocompatibility complex (MHC)
class I or class II molecules on the surface of cortical epithelial
cells, and the strength of the signal delivered to the thymocytes will determine whether the cell dies or is allowed to
complete its maturation (2). Most CD4+CD8+-double-positive
(DP) thymocytes die by neglect, as they fail to express a TCR
that can bind to self-MHC molecules. Less than 5% of the T
cells survive beyond the DP stage, and following positive
selection on self-peptide/MHC complexes, thymocytes
migrate to the thymic medulla where their TCRs are continually assessed for self-reactivity by binding to self-peptide/
MHC complexes expressed on medullary thymic epithelial
cells (MTECs) or myeloid-derived dendritic cells (3). These
specialized antigen-presenting cells (APCs) express the B7
molecules CD80 and CD86, and delivery of a strong TCR
signal triggers death of the T cell (3). The importance of
TCR and CD28 signaling in mediating negative selection and
the generation of regulatory T cells in the thymus has only
been recently appreciated. Thus, CD28 co-stimulation
enhances DP cell apoptosis to low levels of TCR stimuli in
vitro (4), and deficiency of CD28 dramatically exacerbates
autoimmunity in a genetically susceptible background (5).
In addition, NOD (non-obese diabetic) mice that lack expression of CD86 are protected from type 1 diabetes (T1D) but
instead develop an autoimmune neuropathy, which is thought
to arise from a failure to delete a population of neural-specific
auto-reactive T cells in the thymus (6).
A specialized subset of MTECs has been identified in the
thymus that can ectopically express tissue-specific antigens in
the thymus, and the peptide/MHC ligands they present at the
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cell surface are critical for ensuring tolerance to organ-specific
antigens during T-cell development (7, 8). The ectopic
expression of organ-specific antigens is controlled by the
autoimmune regulator gene (AIRE), and loss of AIRE in
humans causes autoimmune polyendocrine syndrome type 1
(APS-1), a rare monogenic disorder that results in widespread
autoimmunity affecting a number of target organs (9–11).
AIRE is expressed in a subset of thymic epithelial cells, and
loss-of-function mutation in the AIRE gene in mice leads to a
milder autoimmune disease phenotype and results in a failure
to eliminate forbidden self-reactive T cells that enter the
periphery to cause disease (12–15).
Defects in negative selection may also arise by a reduction
in thymic expression of individual tissue-specific antigens due
to variation in the promoter sequence of the gene, as illustrated by the human insulin-dependent diabetes mellitus 2
(IDDM2) locus, where susceptibility to anti-insulin autoimmunity is associated with a promoter variant that decreases
thymic insulin expression by several fold (16, 17). Inherited
variation in the efficiency of thymic presentation of tissuespecific peptides, determined by particular MHC allelic variants such as I-Ag7 in NOD mice or HLA-DQ in humans (18),
may also diminish thymic deletion. Thus, an accumulation of
various genetic defects such as those affecting AIRE, MHC, and
tissue expression of target antigens may act synergistically to
disrupt negative selection of forbidden self-reactive T cells and
thus precipitate autoimmune disease.
Although a lot is known about the cellular events arising
from positive and negative selection in the thymus, there is
still relatively little known about the intrinsic cellular signaling
events that result in clonal deletion of self-reactive T cells (3).
A role for z-associated protein of 70 kDa (ZAP-70) was identified through identification of a mouse strain carrying a point
mutation in the Src homology 2 (SH2) domain of ZAP-70
(19). The mutation leads to defective deletion of arthritogenic
T cells, resulting in autoimmune arthritis and joint destruction. There is no single mitogen-activated protein kinase
(MAPK) pathway associated with either positive or negative
selection of thymocytes (20). However, a rapid and transient
burst of extracellular signal-regulated kinase (ERK) signaling
as well as sustained activity of p38 and c-Jun N-terminal
kinase (JNK) kinases acting downstream of TCR favors negative selection that is dependent on the SH2 adapter protein
Grb2 and misshapen–Nck interacting kinase (NIK)-related
kinase (MINK) (20–22). Exactly how the TCR is able to
regulate ERK distinctly from the p38 and JNK kinases during
positive and negative selection is not known. The BH3-only
protein BIM is an important effector protein mediating clonal

Hoyne & Goodnow  Identifying autoimmune regulatory genes in mice

deletion of thymocytes. Bim is upregulated during negative
selection and antagonizes the prosurvival effects of Bcl-2 (23).
Loss of Bim expression leads to a failure in negative selection,
and this loss has been postulated as the basis of the negative
selection defect in thymocytes of NOD mice (24). The nuclear
transcription factor Nur77 is also involved in mediating negative selection of thymocytes, and a dominant negative Nur77
transgene in mice leads to a failure of clonal deletion (25).
Once autoreactive T cells leave the thymus, it appears that
they undergo apoptosis via pathways that are in part distinct
from those used by thymocytes. Peripheral T cells use the
death receptor protein FAS and tumor necrosis factor receptors
(TNFRs). These proteins contain death receptor domains and
associate with adapter proteins such as Fas-associated death
domain (FADD). These adapter proteins can activate downstream caspases to initiate apoptosis. The FAS/FAS ligand
(FASL) signaling is not absolutely required for negative selection of thymocytes, but it can facilitate negative selection to
high-affinity antigens (26–28). Deletion of numerous caspases has no effect on negative selection of thymocytes (3).
However, the loss of FAS or FASL in both mice and humans
has highlighted the essential role these molecules have in
peripheral immune regulation, as mice lacking these genes
develop severe autoimmune syndromes (29–31).

(34, 35). The important immune regulatory function of CBL-B
identified in murine T cells facilitated its identification as a
diabetes susceptibility gene in the Komeda diabetes-prone rat
strain (36). Further work is required to understand how CBL
proteins function with the other ubiquitin ligase proteins to
mediate T-cell anergy and also how the early growth response
genes 2 and 3 (egr2, egr3) facilitate the induction of the
anergic program in T cells (37). There is no clear indication
that mutations in the different ubiquitin ligase genes predispose to autoimmunity in humans. It could be that an accumulation of heterozygous mutations in a number of key
proteins that regulate TCR tuning could be sufficient to disable the anergy program and cause autoimmunity.
The cell surface molecule cytotoxic T-lymphocyte antigen-4
(CTLA-4) is a potent inhibitor of T-cell activation through its
ability to bind with high affinity to the B7 ligands CD80 and
CD86 and to deliver an inhibitory signal to the T cell (38).
The loss of CTLA-4 has a profound effect on immune tolerance, leading to a massive lymphoproliferative disease and
neonatal death (39). The CTLA-4 molecule is expressed constitutively on the surface of regulatory T cells (40, 41), and
the widespread autoimmunity observed in CTLA-4 knockout
mice is thought to arise from the loss of inhibitory signaling
in activated T cells as well as the loss of regulatory T-cell
function.

Antigen receptor tuning

There are several cell-intrinsic mechanisms used to regulate
autoreactive cells in both primary and secondary lymphoid
tissues. The development of T-cell anergy is associated with
downmodulation of TCR expression at the cell surface and a
distinct pattern of signaling downstream of the TCR involving
activation of nuclear factor of activated T cells (NFAT) but not
JNK, activator protein-1 (AP-1), or NF-kB. Thus, chronic,
suboptimal antigen receptor stimulation can induce an inhibitory feedback mechanism that selectively uncouples the TCR
from downstream immunogenic signaling pathways by acting
at the level of the early TCR signalosome (32). This process is
thought to be critical in the establishment of anergy to help
dampen or tune down the TCR signaling in response to
chronic stimulation to self-antigens. A family of ubiquitin
ligases, including CBL-B, ITCH, GRAIL, and NEDD4, are
involved in the internalization of TCR from the cell surface
and the targeting of specific signaling proteins for ubiquitinmediated degradation (33). Studies in mice have identified
that loss of cbl-b can uncouple the co-stimulatory requirements
for naı̈ve T-cell activation, and the dual loss of cbl-b and the
related c-cbl can lead to a large number of activated T cells that
can predispose to the development of autoimmunity in mice

Regulatory T cells
Regulatory T cells play a crucial role in the maintenance of
immune homeostasis and self-tolerance, and they are highly
enriched within the CD4+CD25+ population, which constitutes approximately 5% of the mature CD4+ cell progeny (42).
The recent discovery that the foxp3 gene is a master gene that
directs the formation of CD4+CD25+ cells in vivo and that
expression of this transcription factor is exclusive to this cell
population has provided genetic evidence that they represent a
unique and specialized subset of CD4+ T cells that function to
suppress immune responses (43, 44). CD4+CD25+ T cells
were first defined in mice by Sakaguchi and colleagues (42),
and these cells are found in the peripheral circulation of
humans. In both humans and mice, CD4+CD25+ cells play a
critical role in maintaining the long-term health of the individual (42). Patients with X-linked autoimmunity-allergic
dysregulation syndrome (XLAAD) or immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
as well as the scurfy mouse have a common loss-of-function
mutation in foxp3 that leads to a failure of CD4+CD25+ cell
differentiation, and affected males develop a severe lymphoproliferative disease with a multiorgan inflammatory response
Immunological Reviews 210/2006
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and autoimmunity (42). Although IPEX and XLAAD affect
only a small proportion of people throughout the world, the
fact that these individuals develop life-threatening autoimmune
diseases highlights the importance of CD4+CD25+ T cells to
human health. Despite their significant role in immune homeostasis, many questions remain as how regulatory T cells are
selected in the thymus in response to high-affinity self-antigens
and more importantly how they mediate suppression in vivo (45).
Genomic approaches to identify new autoimmune
regulatory genes
The formation of T cells is perhaps one of the best understood
processes in mammalian cell differentiation, as many genes and
proteins that regulate this process have been identified (46).
Relatively little is known, however, about the genes and proteins
that regulate immunological tolerance. As described above, the
identification of mouse strains with spontaneous mutations in
key immune regulatory genes has been central by providing
insight into the mechanisms of immune tolerance and defining
autoimmune susceptibility genes in humans. Progress hinges
upon new mouse strains with illuminating variants in autoimmune susceptibility genes, yet this approach is limited, because
the rate of natural variation in animal colonies is low. Targeted
mutations by homologous recombination in embryonic stem
cells or RNA interference have been used to introduce germline
mutations, but this strategy relies upon prior knowledge of the
targeted gene that may be of immunological significance.
Moreover, the complete ablation of a protein can obscure
insights into its autoimmune regulatory actions, as illustrated
by the contrasting effects of Zap70 knockout and point mutation
alleles (19, 47, 48). To correct the deficit of new strains, we
need to be able to produce new Mendelian mouse variants that
either develop autoimmunity or display altered immune regulation,
without depending upon prior knowledge about candidate genes or
the way their sequence needs to be altered to reveal their function.
The alkylating agent N-ethyl-N-nitrosourea (ENU) is a very
efficient chemical mutagen of mouse spermatogonial stem cells
that is able to introduce single-point mutations at a rate between
1/100 000 and one in two million base pairs that usually affects
single loci (49, 50). More than 80% of ENU-induced mutations
are either AT to TA transversions or AT to GC transitions (51).
Two-thirds of the variants arising from ENU treatment result in a
change in a single codon resulting in an amino acid replacement,
while the rest of the variants arise due to splicing errors or null
alleles. The rate of mutation induced by ENU is about 100-fold
higher than the rate of spontaneous mutations and about threefold higher than that achieved by X-irradiation. ENU treatment
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yields a new loss-of-function allele in any given gene, on average, one per 1000 gametes, and therefore screening 1000 firstgeneration (G1) offspring should yield at least one heterozygous
loss-of-function mutation in the majority of immune regulatory
genes (52, 53).
The gene knockout approach tends to result in the loss of
expression of the whole protein. This loss can obscure key
immunoregulatory functions of the protein, especially if it
must interact with other proteins to mediate its function.
Alternatively, naturally occurring mutations that give rise to
missense alleles can disrupt important functional domains
within proteins and lead to ‘separation-of-function’ alleles.
These new variant alleles can reveal more information about a
protein that would not have been previously identified had the
gene been knocked out. There are now several examples where
single-base substitutions in the mouse genome sequence, by
causing amino acid substitutions in ZAP-70, Ikaros, linker for
activated T cells (LAT), and Carma-1, have revealed inhibitory
roles of these proteins in immune regulation that were
obscured by complete protein ablation (19, 54–57).
To perform a genomewide screen with single-base substitutions, male founder mice are treated with ENU and mated
with wildtype mice to yield G1 progeny. The G1 progeny
themselves or their second-generation (G2) offspring can be
screened for dominant variants. Alternatively, the progeny of
individual G1 mice can be inbred for two generations so that
recessive variants can come to homozygosity in their G3
progeny. Large-scale dominant screens have been carried out
by several centers around the world that have focused on
phenotypes ranging from visible phenotypes to immunological, biochemical, and behavioral phenotypes (58, 59). Other
groups like our own have taken a more focused approach to
address a key biological process such as immune regulation.
The Beutler group (60–63) has used a genome mutagenesis
screen to make remarkable advances in our understanding of
the genes involved in regulating innate immune mechanisms.
We have used genomewide screens designed to identify genes
involved in lymphocyte differentiation as well as screens for
systemic autoimmune diseases, immunization responses
(54, 57, 64–66), and as we discuss here, a sensitized screen
that encompasses a model of organ-specific autoimmune
disease resulting in the development of T1D.
Rationale for a sensitized screen to identify autoimmune
regulatory genes in diabetes
While entirely novel immune regulatory mechanisms are
revealed by sequence variants induced in a simple inbred
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strain such as C57BL/6 (65, 66), two factors constrain this
approach. First, for diseases such as T1D, loss of function in
important regulatory genes will often be insufficient to precipitate diabetes on their own. This point is illustrated by the
Komeda diabetes-prone rat model, where homozygosity for a
stop codon in cbl-b must be combined with a susceptible MHC
haplotype and other loci for autoimmune diabetes to manifest
(36). Similarly, AIRE deficiency in mice only leads to autoimmune gastritis or T1D when combined with a sensitized/
susceptible genetic background (15, 67). Thus, a solution to
this constraining factor is to perform ENU mutagenesis in an
already diabetes-sensitized strain, where defects in individual
regulators will be obvious.
The second constraining factor stems from the fact that
many genes that contribute to protecting us from autoimmune diabetes will also perform other essential functions.
Homozygous loss of function in these genes will often cause
embryonic or neonatal lethality and hence fail to be detected
as diabetes regulators. A solution to this constraint has been
established in Drosophila, by performing mutagenesis in a sensitized strain where the process of interest (e.g. eye patterning) has already been partially crippled (68, 69). In these
sensitized stocks, loss of a single copy of a gene supporting
the process is now sufficient to disrupt that process, while
remaining sufficient for development and viability. As
described here, we have established a diabetes-sensitized indicator strain of mice, which reveals heterozygous lossof-function variants in single genes that normally would be
recessive, lethal, or undetected.

The TCR:InsHel model
The 3A9 TCR transgenic mouse is the basis of our sensitized
screen to identify autoimmune regulatory genes in mice. The
TCR encoded by this transgene recognizes with high affinity
the immunodominant peptide of hen egg lysozyme (HEL) 46-61
presented in association with I-Ak. Several partner strains of
transgenic mice have been engineered to express the HEL
protein as a neo-self-antigen under different tissue-specific
promoters (Table 1). We have focused on the well-characterized
TCR:InsHel double transgenic combination for the purposes
of the sensitized screen (70, 71), because it is on the brink of
developing T1D, such that heterozygous defects in single
genes (e.g. in Roquin, Aire, and cbl-b) are sufficient to precipitate
overt diabetes (15, 65, GH and CG, unpublished data), as
are single-gene defects in thymic deletion, regulatory T-cell
formation, and peripheral anergy.

The TCR:InsHel strain is ideally suited as a model to the
study of the development of immune tolerance to an organspecific self-antigen. The neo-self-antigen HEL is highly
expressed on pancreatic b cells and is expressed in an AIREdependent manner in thymic medullary epithelium. While
there is no insulitis or autoimmunity in single transgenic
insHEL or TCR animals, in TCR:insHEL-double-transgenic
(Dbl) mice, the pancreatic islets become infiltrated with leukocytes within 3–4 weeks of age yet do not progress to
diabetes in the majority of animals. This preclinical phase of
insulitis occurs only with the TCR:InsHel mice and is similar
to the preclinical disease process that occurs in NOD mice
(72). To generate Dbl (TCR:InsHel) mice, 3A9 TCR mice are
mated with InsHel transgenic mice. Both transgenes must be
kept in a hemizygous state, requiring one of two breeding pair
combinations: (i) TCR  InsHel or (ii) Dbl  non-transgenic
mice. As the transgenes segregate independently at each generation, offspring are of four equally frequent genotypes:
non-transgenic, TCR, InsHel, or Dbl. Only the Dbl offspring
are sensitized to diabetes, allowing new diabetes susceptibility
gene variants to be propagated from healthy carriers among
the non-sensitized siblings.
On a wildtype B10.BR background, we observe a background incidence of diabetes at a frequency of 20% of the
Dbl mice (72). Those animals that develop diabetes do not
appear to have a complete breakdown of tolerance to insHEL,
as they do not produce immunoglobulin G (IgG) antibodies
to the HEL protein. By contrast, TCR:InsHel mice bred on the
NOD-H2k background do exhibit a complete breakdown in
T-cell tolerance, with >90% of Dbl animals developing
diabetes, formation of germinal centers in the pancreatic
islets, and secretion of high titers of anti-HEL IgG in the
serum (72). A further advantage of the 3A9 model is that
we can track the fate of the Hel-reactive CD4+ T cells in vitro
and in vivo with the use of a TCR clonotype-specific monoclonal antibody (1G12) to determine the frequency of
Hel-reactive T cells in either TCR or TCR:InsHel mice using
flow cytometry (14, 72). This analysis provides an early
insight into the cellular mechanisms that may be disrupted
by new gene variants identified in the screen.
Pedigree structure to screen for gene variants that
precipitate T1D
The majority of sequence variants that are generated by ENU
treatment will be recessive mutations, and to identify new
sequence variants in ENU-treated gametes, we use a threegeneration breeding structure to bring recessive mutations to
Immunological Reviews 210/2006
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Table 1. Properties of T-cell deletion in different TCR · Hel transgenic mouse strains
Strain
TCR:
TCR:
TCR:
TCR:

InsHel
thyr:hel
Membrane:Hel
Soluble:Hel

Transgenic promoter

Tissue expression

Stage of negative selection

Rat insulin
thyrogobulin
Class I MHC (H2k)
metallothionein

Pancreatic b- cells and thymus
thyroid
All somatic cells
Peripheral circulation

Early and late CD4 SP
DP and early CD4 SP
DP
Early and late singel positive CD4

homozygosity (Fig. 1). By establishing large numbers of G3
pedigrees, it is possible to simultaneously screen hundreds of
genes for their autoimmune regulatory potential. The C57BL/
6J strain is routinely used in ENU mutagenesis. Their spermatogonial stem cells are exquisitely sensitive to the alkylating
agent ENU, and the male mice readily regain their fertility
(52, 53). Following ENU treatment, founder G0 B6 male
mice (prepared in batches of 20–50) are bred with female
B10.BR (H2k) TCR:InsHel transgenic mice (Fig. 1). Each G1
mouse is estimated to carry an independent set of approximately 30 loss-of-function variants on the paternal chromosomes, based on the average of new loss-of-function variants
per gamete (1/1000) and the number of mammalian genes
(approximately 30 000 genes). The TCR, InsHel, and H2 genes,
as well as the variant alleles induced by ENU, all segregate
independently within the offspring at each generation. All G1,
G2, and G3 mice are genotyped for HEL, TCR, and H2 by
polymerase chain reaction (PCR) tests performed on earpunch biopsies prepared in bar-coded 96-well plates. As we
are restricted to breeding TCR:InsHel  non-transgenic or

TCR  InsHel mice, we use a brother  sister pairing with
the complementary genotype at each generation until we
reach G3. The G3 mice are screened for the onset of T1D,
which is identified by the presence of a wet cage with a cutoff
at 24 weeks of age.
Diabetic animals in the ENU screen are first identified by
the presence of a wet cage. The affected mouse is tested for
urine glucose by diastix, and the levels of blood glucose are
also monitored. Unless treated, diabetic mice become unwell
and begin to lose weight within several weeks, precluding any
possibility of breeding to transmit the desired gene variants
that they carry. This problem has been solved neatly by
establishing a diabetes curative regime that enables the longterm health and breeding of individual diabetic mice that
carry variant alleles of autoimmune regulatory genes. Once
the diagnosis of T1D is made, the affected animals initially
receive daily subcutaneous insulin injections to stabilize their
blood glucose. This treatment prevents weight loss and allows
growth, but they usually do not breed. To cure the animals of
diabetes permanently, they receive a pancreatic islet transplant

ENU

G0 B6

Each G1 carries≈3000
single nucleotide
substitutions
(6000 in total) in
heterozygous state

B10.BR
TCR:InsHel

G1

≈1500 single nucleotide
substitutions carried by
both G2 per pair

Breeder set up:
TCR:InsHel × non
or
TCR × InsHel

G2

G3
≈375 homozygous
mutations in any G3
mouse
Expect 25% offspring to be TCR:InsHel
Expect 25% to have homozygous recessive mutation
Expect 1/16 TCR:InsHel mice to carry homozygous recessive mutation @G3
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Fig. 1. Pedigree structure for the ENU type
1 diabetes screen. The three-generation
breeding structure is designed to bring
recessive mutations to homozygosity in G3
animals. G1 mice that carry about 100 loss-offunction alleles are intercrossed with female
G1 mice by breeding TCR:InsHel  nontransgenic or TCR  InsHel mice. ENU,
N-ethyl-N-nitrosourea.
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from syngeneic non-transgenic donor mice, given under the
kidney capsule. Following surgery, the animal’s blood glucose
levels return within the normal range within 1–2 weeks
(Fig. 2). As the transplanted islet cells are derived from nontransgenic donors, they do not express HEL antigen and are
ignored by the transgenic autoreactive T-cell repertoire. It
should be noted that the diabetic animals also receive no
other form of immune suppression after transplant. Our
experience is that this maneuver cures diabetes long-term,
so that the mice begin to breed within 2–4 weeks of surgery
and thrive to 12–18 months of age.
Criteria for screening for T1D
A challenge posed by most sensitized screens is the inevitable
existence of a background level of phenocopies due to nongenetic sources of variation. In our case, this background is
manifest by a 20% incidence of diabetes in wildtype
TCR:InsHel mice, with onset around 8–10 weeks of age
(72) (Fig. 3). We employ four strategies to filter out this
source of false-positive results. First, high priority is given to
animals that develop diabetes at <7 weeks of age, as this time
of onset is very rare in the wildtype stock (Fig. 3). Second,
high priority is given to animals that are found by enzymelinked immunosorbent assay (ELISA) to have IgG antibodies
against HEL in their serum, as this does not occur as part of
the background diabetes in the wildtype stocks (72). In addition to testing each mouse that develops diabetes, healthy G3
Dbl mice are routinely screened for the presence of anti-HEL
IgG antibodies at 8–10 weeks of age to predict those animals
that may be at risk of developing T1D. Any animals scoring
positive in the primary screen are re-bled to confirm their

positive test, and upon confirmation, the mice are used for
breeding. Third, we give high priority to Dbl animals of H2kb
genotype that develop diabetes, as there is <3% incidence of
diabetes in wildtype H2kb Dbl mice. Positive selection of the
3A9 TCR is inefficient in H2kb heterozygous animals, so that
there is a larger repertoire of other TCR a chains that normally
prevents any progression to diabetes. Fourth, animals with a
high frequency of Dbl siblings that develop diabetes are given
higher priority, as this familial clustering suggests heritable
variants, especially for dominant or semidominant alleles.
Finally, the diabetic animals are progeny-tested after being
cured by islet transplantation, with the expectation that 50%
of their Dbl offspring will be diabetic. This frequency is
expected either if they carry a dominant trait that has been
outcrossed to B10.BR or if the index diabetic animal was
homozygous for a recessive variant and was intercrossed
with a G3 sibling that is likely to be a heterozygous carrier.
As the same criteria must also be able to be applied to map
the variants in an intercross with another inbred strain, we
also have established the background incidence in wildtype
stocks of Dbl (TCR:insHEL) mice intercrossed and backcrossed
to the CBA/H strain. To date, the B10.BR  CBA/H Dbl mice
backcrossed four generations on the CBA background display
an identical disease incidence (Fig. 3) to the B6  B10.BR Dbl
animals, and the background incidence of diabetes on the
mixed or backcross background is also not accompanied by
secretion of anti-HEL IgG antibodies.
Further improvements to the sensitized screen
The establishment of a phenotypically matched counterpart
of CBA/H TCR:insHEL animals, as described above, has in
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Fig. 2. Monitoring of blood glucose in Dbl
(TCR:insHEL) diabetic variant mice following non-transgenic islet transplant. The
figure shows the blood glucose measurements
of 12 different diabetic Dbl animals identified
through the ENU screen. Typically, the diabetic
animals have a blood glucose level of >20.
Following transplant under the kidney capsule
of syngeneic islet cells, the blood glucose
returns to a normal level (<10) within a week
of the transplant and remains normal for the
life of the animal without any immunosuppression. ENU, N-ethyl-N-nitrosourea.
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Yield from the sensitized diabetes screen
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Fig. 3. Background incidence of diabetes in wildtype Dbl
(TCR:InsHel) mice. The figure shows the diabetes incidence curves for
Dbl mice on the B10.BR background and different generations of backcrossing the transgenes to the CBA background. On average, the disease
onset occurs between 8 and 10 weeks of age with a peak incidence of
20–25%, and none of the diabetic animals generate anti-Hel IgG antibodies. Thus, in the mutagenized stocks, high priority is given to variant
animals with diabetes onset at <7 weeks old and/or accompanied by
anti-HEL IgG.

turn enabled two additional improvements in the screen to
accelerate each step of the screen. As illustrated in Fig. 4,
rather than constructing libraries as an intercross between
ENU-treated B6 mice and TCR:insHEL transgenic B10.BR
mice, the latter are now substituted by CBA/H TCR:insHEL
animals. As a result, the G1 founders of each pedigree are
(B6  CBA)F1 hybrids, which has a powerful effect on their
breeding performance by introducing a high level of hybrid
vigor. These G1 founders are backcrossed with wildtype
CBA/H animals of complementary TCR and insHEL genotype. Their G2 offspring are (B6>CBA)N2 backcross animals, retaining strong hybrid vigor when they are in turn
mated to their G1 parent, so that the yield of G3 mice from
each mating is greatly enhanced compared to B6  B10.BR
pedigrees. This mating enables pedigrees to reach the target
number of G3 Dbl indicator offspring much more quickly
and efficiently. The second advantage of this strategy is that
the G3 animals are already at a mapping generation when
they are discovered, enabling a chromosomal assignment
either at this point or in their immediate offspring from
progeny testing. A variation on this approach, which has
also proved successful (used in a library called ENU 6CAT),
has been to induce single-nucleotide substitutions in CBA/H
mice and then intercross with B10.BR TCR:insHEL animals to
yield pedigrees with vigorous breeding and early mapping in
the same way.
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We have screened 261 G3 pedigrees and identified 42 strains
with demonstrated heritable increase in diabetes susceptibility
(Table 2). This finding represents a 16% hit rate per pedigree,
which is higher than the 10% hit rate obtained for screens on
lymphocyte abnormalities in blood lymphocyte subsets and
lower than the 30% hit rate obtained with screens for an
early surrogate indicator of susceptibility to systemic autoimmunity based on presence of anti-nuclear antibodies in serum
(46, 66). The majority of strains 36/42 (or 86%) identified in
the T1D screen behave as recessive mutations, whereas 6/42 or
(14%) are dominant traits, which means that the loss of a single
copy of the variant allele is sufficient to induce diabetes
(Table 2). Approximately 30% of the T1D strains produce antiHEL IgG antibodies, possibly indicating mutations in genes that
control peripheral regulation of HEL-reactive CD4+ T cells.

Mapping and sequencing the new diabetes-susceptible
variants
Once a true breeding diabetes variant is identified, the process
of linkage mapping through intercrosses follows a strategy of
outcrossing the mice to the CBA/H strain to provide the
genetic polymorphisms that will allow the use of simple
sequence length polymorphisms (SSLPs) or single-nucleotide
polymorphisms (SNPs) to initially identify chromosome linkage (66, 73). The choice of the mapping strain is dictated by
the necessity to maintain the correct H2 haplotype to enable
the 3A9 TCR to undergo efficient positive selection. It is for
this reason that the CBA/H strain has been used as the mapping partner for the ENU 4AT, 5AT, and 6AT libraries, as
mutations in each of these libraries are transmitted on chromosomal DNA originating from the founder C57BL/6 (H2b)
parent. For the ENU 6CAT library, we use the B10.BR strain,
as the mutations are carried on a CBA chromosomal segment
originating from the G0 parent.
We can determine in the first backcross to the mapping
strain whether or not the mutation is dominant, and if so, we
continue to backcross the F1 mice onto CBA mice to generate
an N2 generation. If no diabetes is observed in the F1 progeny, we assume that the mutation is recessive, and the F1
siblings are mated as TCR:InsHel  non-transgenic or
TCR  InsHel. The F2 progeny are scored for T1D. We expect
25% of the F2 offspring to be homozygous for the mutation
and only 25% of the offspring to be a TCR:insHEL mouse.
Therefore, we expect only 1/16 F2 mice to be a TCR:InsHel
mouse and to carry a homozygous mutation. We need to
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ENU8CAT pedigrees founded by G1 male
ENU
G0 C57BL/6

TCR+ HEL+ AT→CBA N3, N2 (or F2IC if
short) OK if use HEL+ or TCR+ animals also
AT→CBA N4, N3 or N2: transgene
status complementary to G1 mouse

G1 male offspring are (B6 × CBA)F1 hybrids
Genotype test: Expect 1/4 HEL+, TCR+, Dbl+ & Non.
All are H-2kb, so don't need genotyping for H-2kb.

ie breed HEL+ × TCR+, Dbl+ × non-Tg

G2 daughters are BC1 to Strain A
Wean >8 female G2s, and genotype for TCR.
HEL, H-2kb. Select a G2 female that is
complementary transgene status to G1 so that
breed HEL+ × TCR+ or Dbl+ × non-Tg, Half will
be H-2kk and half H-2kb: prefer H-2kk for
breeding where available. Only 1/4 of female
G2 offspring will be correct, so will need to wean
and type >8 female G2 offspring

G3 offspring: Equivalent to F21C
for mapping recessives
One quarter are Dbl+, H-2 will be variable.
One quarter are homozygous for any variant carried by the G2
mother
Genotype 32 G3 offspring for HEL and TCR (not H-2), keeping
only the Dbl+ animals, which are aged to 4 months: expect 8
Dbl+/pedigree, and 2 homozygotes on Dbl+background

Once an interesting variant is known to exist in a pedigree will need to propagate the strain and determine its map location by:
(i)

crossing affected animal with G1 father (50% of offspring will be B6 homozygous for the variant locus, and no unlinked loci
will be fixed in the affected variant G4 animals):

(ii)

crossing at least two unaffected siblings separately with G1 father (25% of offspring homozygous for variant B6 locus, no
unlinked loci fixed in G4)

(iii) intercrossing at least five pairs of unaffected siblings (1/64 loci will be randomly fixed as B6 homozygous in G4 progeny from any
one pair)
(iv) backcrossing affected individual to CBA and intercrossing offspring (this is cleanest, but slowest option)

Fig. 4. An improved pedigree structure to enhance the identification and mapping of new autoimmune variant strains in the latest ENU
library. ENU, N-ethyl-N-nitrosourea.

Table 2. Summary of diabetes screening in multiple G3 progeny
Disease
Type 1 diabetes

Number
Number
Number
Number
Number

of
of
of
of
of

G3 pedigrees screened
diabetic strains confirmed
recessive mutations
dominant mutations
anti-Hel IgG+ strains

Type 2 diabetes

4AT

5AT

6AT

6CAT

Total

105
10
9
1
5
0

54
3
3
0
0
0

62*
15
13
2
5
2

40*
14
12
3
3
0

261
42
36
6
13
2

* These libraries have not finished G3 screen

breed at least 64 F2 progeny from one breeder pair to be
confident that we score enough F2 TCR:InsHel mice to ensure
that the mutation is heritable.
We have used two different strategies to map mutations in
the ENU-induced variant mice. The first strategy uses a pooled
DNA approach. DNAs from 15–20 affected F2 TCR:InsHel

mice are tested for a high proportion of B6-derived chromosomal regions by PCR amplification and agarose gel of SSLP
markers spaced at about 20 cM, which gives between three
and four markers per chromosome. Alternatively, if there are
fewer than 10 affected TCR:InsHel F2 mice, we can screen the
individual mice for the various SSLP markers at the ends of the
Immunological Reviews 210/2006
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chromosome using the method of Beier (49). The linked
interval is confirmed and narrowed by individually typing
each mouse sample with additional SSLP makers that span
the region of linkage. We have also developed a mapping
method based on SNPs that naturally occur between the different strains (e.g. B6, B10, and CBA/H). This latter technique
is a fluorescence-based assay and takes away the requirement
of agarose gel electrophoresis completely. The fluorescent SNP
analysis can be used in exactly the same way as the original
SSLP markers, i.e. as a pooled strategy or screening of individual affected mice.
Once a region of linkage is identified, it is necessary to
reduce the interval to within 1–2 Mb. This reduction requires
screening subsequent F2 or N2 mice for two flanking markers
that span the region of interest to identify useful recombinants
that can help narrow the interval. It is possible to use a
candidate gene approach to examine genes within the interval
that might be expected to give a phenotype similar to that of
the mutant animal, and it is possible to sequence the gene(s).
Once the region has been reduced to 1–2 Mb, the region will
hopefully contain <30 genes, and all of the mRNAs encoded
in the interval may be sequenced. PCR amplification is used to
generate overlapping 700-bp fragments of the candidate gene
sequence, and these are gel-purified and sequenced. Typically
75% of ENU variants have single-nucleotide substitutions that
lead to amino acid substitutions in the primary amino acid
sequence. These can disrupt functional domains on the protein, and 25% can be alterations in mRNA splicing.
Phenotypic analysis of the T1D mutant mice
The primary aim following screening of affected G3 mice is to
establish a true breeding strain. Until we have established the
strain, minimal phenotypic analysis is performed on the variant strains. Once established, the mutant diabetic animals are
screened by fluorescence-assisted cell sorting (FACS) analysis
to determine what effect the mutation might have on negative
selection in the thymus, using an approach similar to that used
by Liston et al. (14, 72). Irradiation chimeras are employed to
determine whether the mutation acts cell-autonomously, and
this finding indicates whether the mutation is likely to be
involved in signal reception or transduction. Alternatively,
the mutation may behave non-autonomously, which may be
the case if the mutation affected antigen presentation by APCs,
regulatory T-cell action, or a failure to secrete a cell–cell acting
cytokine.
An example is provided in Fig. 5 that shows analysis of
wildtype and a diabetic mutant mouse arising in strain 4AT
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24. Susceptibility to T1D in this strain is inherited in a dominant manner, but there is no significant expansion of the Helreactive (CD4+1G12+) T cells in the peripheral tissues of the
diabetic mice. We conclude that thymic negative selection is
normal in these animals and that the mutation instead affects
some aspect of the peripheral regulation of the autoreactive T
cells. This conclusion is supported by the finding that approximately 50% of the diabetic animals in this strain make high
titers of anti-Hel IgG in their serum.
Translating the findings from mice to humans
The development of immunological tolerance is essential to
prevent the development of autoimmune diseases. Although
we understand much about the cellular aspects of tolerance
induction to self-antigens, there is still a major gap in our
knowledge about the number and identity of the genes
involved in this process. Several genes that regulate clonal
deletion of forbidden self-reactive lymphocytes (e.g. Aire,
BIM, and MINK) and antigen receptor tuning (c-Cbl, Cbl-b,
Grail, etc.) have already been defined, but hundreds more are
likely to be involved in regulating self-tolerance to organspecific and systemic self-antigens. By generating new
mouse variants through controlled variation of the genome
sequence with ENU, a rich resource for new animal models
for the study of autoimmunity is provided that may allow us
to probe more deeply into the mechanisms and pathways
central to the induction and maintenance of tolerance. As the
full sequence of both the mouse and human genomes is
available, it should be possible to translate findings from
mice to humans relatively quickly. As was the case for foxp3
and Fas, defining autoimmune regulatory genes in mouse
strains will illuminate orthologous human genes as candidates
for sequence and functional variation that may explain human
autoimmune susceptibility. As most human autoimmune diseases are likely to be polygenic, unlike that of APS-1 which is
caused by a single-gene defect in Aire or XLAAD/IPEX caused
by a mutation in foxp3, it may be that those patients with
susceptibility to autoimmunity accumulate a number of heterozygous mutations in key regulatory genes that control a
pathway or a process, and it is the sum of these mutations that
act in combination to cause a breakdown in self-tolerance and
autoimmunity. Thus, the information gained from analysis of
each new variant mouse strain will begin to build a detailed
cellular map of the key developmental checkpoints involved in
lymphocyte development and in immunological tolerance,
and this map should advance our understanding of the same
process in humans.
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Fig. 5. Example of a strain identified in the ENU 4AT library that
carries a dominant mutation predisposing to T1D. (A) The genealogy
tree shows only the TCR:InsHel mice born at each generation for simplicity. The filled symbols represent diabetic animals, and the striped
symbols represent diabetic mice that also make anti-HEL IgG antibodies.
The open symbols are non-diabetic offspring, and symbols with bars
across represent TCR:InsHel offspring that died. (B) Phenotypic analysis
of a wildtype TCR transgenic and a TCR:InsHel mouse compared to a
mutant TCR:InsHel mouse. The top panel shows the analysis of CD4

versus CD8 T-cell differentiation, and the lower panel shows the
expression of the clonotype TCR+ cells at the late CD4-singlepositive stage of development. The lower two panels show the
frequency of CD4+1G12+ T cells in the spleen and the blood,
respectively, for the different strains analyzed. (C) The diabetes
incidence curve for N2 generation mice studied over a 24-week
period. N2 mice with diabetes onset before 7 weeks old are used for
mapping the susceptibility gene variant. ENU, N-ethyl-N-nitrosourea;
T1D, type 1 diabetes.

References
1. Goodnow CC, Sprent J, Fazekas de St Groth B,
Vinuesa C. Cellular and genetic mechanisms
of self tolerance and autoimmunity. Nature
2005;435:590–597.
2. Love PE, Chan AC. Regulation of thymocyte
development: only the meek survive. Curr
Opin Immunol 2003;15:199–203.
3. Palmer E. Negative selection – clearing out
the bad apples from the T-cell repertoire. Nat
Rev Immunol 2003;3:383–391.
4. Punt JA, Osborne BA, Takahama Y, Sharrow SO,
Singer A. Negative selection of CD4+CD8+
thymocytes by T cell receptor-induced

apoptosis requires a costimulatory signal that
can be provided by CD28. J Exp Med
1994;179:709–713.
5. Salomon B, et al. B7/CD28 costimulation is
essential for the homeostasis of the CD4+
CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity
2000;12:431–440.
6. Salomon B, et al. Development of spontaneous autoimmune peripheral polyneuropathy
in B7-2-deficient NOD mice. J Exp Med
2001;194:677–684.

7. Hanahan D. Peripheral-antigen-expressing
cells in thymic medulla: factors in self-tolerance
and autoimmunity. Curr Opin Immunol
1998;10:656–662.
8. Kyewski B, Derbinski J, Gotter J, Klein L.
Promiscuous gene expression and central
T-cell tolerance: more than meets the eye.
Trends Immunol 2002;23:364–371.
9. Peterson P, et al. APECED: a monogenic
autoimmune disease providing new clues to
self-tolerance. Immunol Today
1998;19:384–386.

Immunological Reviews 210/2006

37

Hoyne & Goodnow  Identifying autoimmune regulatory genes in mice

10. The Finnish-German Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type
zinc-finger domains. The Finnish-German
APECED Consortium. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat Genet 1997;17:399–403.
11. Nagamine K, et al. Positional cloning of the
APECED gene. Nat Genet 1997;17:393–398.
12. Ramsey C, et al. Aire deficient mice develop
multiple features of APECED phenotype and
show altered immune response. Hum Mol
Genet 2002;11:397–409.
13. Anderson MS, et al. Projection of an immunological self shadow within the thymus
by the aire protein. Science 2002;298:
1395–1401.
14. Liston A, Lesage S, Wilson J, Townsend M,
Goodnow C. Organ-specific T cells escape
thymic censoring as a result of autoimmune
polyendocrinopathy syndrome 1 mutation.
Nat Immunol 2003;4:350–354.
15. Liston A, et al. Gene dosage–limiting role of
Aire in thymic expression, clonal deletion,
and organ-specific autoimmunity. J Exp Med
2004;200:1015–1026.
16. Vafiadis P, et al. Insulin expression in human
thymus is modulated by INS VNTR alleles at
the IDDM2 locus. Nat Genet 1997;15:
289–292.
17. Pugliese A, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at
the INS VNTR-IDDM2 susceptibility locus
for type 1 diabetes. Nat Genet 1997;15:
293–297.
18. Todd J, Wicker L. Genetic protection from
the inflammatory disease type 1 diabetes in
human and animal models. Immunity
2001;15:387–395.
19. Sakaguchi N, et al. Altered thymic T-cell
selection due to a mutation of the ZAP-70
gene causes autoimmune arthritis in mice.
Nature 2003;426:454–460.
20. Werlen G, Hausmann B, Naeher D, Palmer E.
Signaling life and death in the thymus: timing
is everything. Science 2003;299:1859–1863.
21. McCarty N, Paust S, Ikizawa K, Dan I, Li X,
Cantor H. Signaling by the kinase MINK is
essential in the negative selection of autoreactive thymocytes. Nat Immunol
2005;6:65–72.
22. Gong Q, et al. Disruption of T cell signaling
networks and development by Grb2 haploid
insufficiency. Nat Immunol 2001;2:29–36.
23. Bouillet P, et al. BH3-only Bcl-2 family
member Bim is required for apoptosis of
autoreactive thymocytes. Nature
2002;415:922–926.
24. Liston A, et al. Generalized resistance to thymic
deletion in the NOD mouse: a polygenic trait
characterized by defective induction of Bim.
Immunity 2004;21:817–830.

38

25. Zhou T, et al. Inhibition of Nur77/Nurr1
leads to inefficient clonal deletion of selfreactive T cells. J Exp Med 1996;183:
1879–1892.
26. Kotzin BL, Babcock SK, Herron LR. Deletion
of potentially self-reactive T cell receptor
specificities in L3T4-, Lyt-2- T cells of lpr
mice. J Exp Med 1988;168:2221–2229.
27. Kishimoto H, Surh CD, Sprent J. A role for Fas
in negative selection of thymocytes in vivo.
J Exp Med 1998;187:1427–1438.
28. Sprent J, Kishimoto H. The thymus and
negative selection. Immunol Rev
2002;185:126–135.
29. Ferguson TA, Stuart PM, Herndon JM,
Griffith TS. Apoptosis, tolerance, and regulatory T cells – old wine, new wineskins.
Immunol Rev 2003;193:111–123.
30. Green DR, Droin N, Pinkoski M. Activationinduced cell death in T cells. Immunol Rev
2003;193:70–81.
31. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosisinducing Fas receptor: a lesson from the
mouse model. J Hum Genet 1998;43:2–8.
32. Jun J, Goodnow CC. Scaffolding of antigen
receptors for immunogenic versus tolerogenic signaling. Nat Immunol 2003;4:
1057–1064.
33. Mueller D. E3 ubiquitin ligases as T cell
anergy factors. Nat Immunol 2004;5:
883–890.
34. Bachmaier K, et al. Negative regulation of
lymphocyte activation and autoimmunity by
the molecular adaptor Cbl-b. Nature
2000;403:211–216.
35. Chiang YJ, et al. Cbl-b regulates the CD28
dependence of T-cell activation. Nature
2000;403:216–220.
36. Yokoi N, et al. Clbb is a major susceptibility
gene for rat type1 diabetes mellitus. Nat
Genet 2002;31:391–394.
37. Safford M, et al. Egr-2 and Egr-3 are negative
regulators of T cell activation. Nat Immunol
2005;6:472–480.
38. Salomon B, Bluestone JA. Complexities of
CD28/B7: CTLA-4 costimulatory pathways in
autoimmunity and transplantation. Annu Rev
Immunol 2001;19:225–252.
39. Waterhouse P, et al. Lymphoproliferative
disorders with early lethality in mice deficient
in Ctla-4. Science 1995;270:985–988.
40. Read S, Malmstrom V, Powrie F. Cytotoxic T
lymphocyte-associated antigen 4 plays an
essential role in the function of
CD25(+)CD4(+) regulatory cells that control
intestinal inflammation. J Exp Med
2000;192:295–302.
41. Takahashi T, et al. Immunologic selftolerance maintained by CD25(+)CD4(+)
regulatory T cells constitutively expressing
cytotoxic T lymphocyte-associated antigen 4.
J Exp Med 2000;192:303–310.

Immunological Reviews 210/2006

42. Sakaguchi S. The origin of FOXP3-expressing
CD4+ regulatory T cells: thymus or periphery. J Clin Invest 2003;112:1310–1312.
43. Hori S, Nomura T, Sakaguchi S. Control of
regulatory T cell development by the transcription factor Foxp3. Science
2003;299:1057–1061.
44. Fontenot JD, Gavin MA, Rudensky AY. Foxp3
programs the development and function of
CD4+CD25+ regulatory T cells. Nat
Immunol 2003;4:330–336.
45. Jordan M, et al. Thymic selection of CD4+
CD25+ regulatory T cells induced by an
agonist self-peptide. Nat Immunol
2001;2:301–306.
46. Papathanasiou P, Goodnow CC. Connecting
mammalian genome with phenome by ENU
mouse mutagenesis: gene combinations specifying the immune system. Annu Rev Genet
2005;39:241–262.
47. Negishi I, et al. Essential role for ZAP-70 in
both positive and negative selection of
thymocytes. Nature 1995;376:435–438.
48. Wiest DL, et al. A spontaneously arising
mutation in the DLAARN motif of murine
ZAP-70 abrogates kinase activity and arrests
thymocyte development. Immunity
1997;6:663–671.
49. Beier D. Sequence-based analysis of mutagenized mice. Mamm Genome
2000;11:594–597.
50. Coghill E, et al. A gene driven approach to the
identification of ENU mutants in the mouse.
Nat Genet 2002;30:255–256.
51. Justice MJ, Noveroske J, Weber J, Zheng B,
Bradley A. Mouse ENU mutagenesis. Hum
Mol Genet 1999;8:1955–1963.
52. Hitosumachi S, Carpenter D, Russel L. Doserepetition increases the mutagenic effectiveness of N-ethyl-N-nitrosourea in mouse
spermatogonia. Proc Natl Acad Sci USA
1985;82:6619–6621.
53. Lyons M, Morris T. Mutation rates at a new
set of specific loci in the mouse. Genet Res
1966;7:12–17.
54. Papathanasiou P, et al. Widespread failure of
hematolymphoid differentiation caused by a
recessive niche-filling allele of the Ikaros
transcription factor. Immunity 2003;19:
131–144.
55. Aguado E, et al. Induction of T helper type 2
immunity by a point mutation in the LAT
adaptor. Science 2002;296:2036–2040.
56. Sommers C, et al. A LAT mutation that
inhibits T cells development yet induces
lymphoproliferation. Science 2002;296:
2040–2043.
57. Jun J, et al. Selectively crippled immunogenic
responses and atopy in mice with an ENU
induced point mutation in the PDZ protein
Carma-1. Immunity 2003;18:751–762.

Hoyne & Goodnow  Identifying autoimmune regulatory genes in mice

58. Nolan P, et al. A systematic, genome wide,
phenotype driven mutagenesis programme
for gene function studies in the mouse. Nat
Genet 2000;25:440–443.
59. Hrabe de Angelis M, et al. Genome-wide,
large scale production of mutant mice by
ENU mutagenesis. Nat Genet 2000;25:
444–447.
60. Jiang Z, et al. CD14 is required for MyD88independent LPS signaling. Nat Immunol
2005;6:565–570.
61. Hoebe K, et al. Identification of Lps2 as a key
transducer of MyD88-independent TIR signalling. Nature 2003;424:743–748.
62. Hoebe K, et al. CD36 is a sensor of diacylglycerides. Nature 2005;433:523–527.
63. Beutler B, Crozat K, Koziol J, Georgel P.
Genetic dissection of innate immunity to
infection: the mouse cytomegalovirus model.
Curr Opin Immunol 2005;17:36–43.

64. Miosge LA, Blasioli J, Blery M, Goodnow CC.
Analysis of an ethylnitrosourea-generated
mouse mutation defines a cell intrinsic role of
nuclear factor kappaB2 in regulating circulating B cell numbers. J Exp Med
2002;196:1113–1119.
65. Vinuesa C, et al. A RING-type ubiquitin ligase
family member required to repress follicular
helper T cells and autoimmunity. Nature
2005;435:452–458.
66. Vinuesa C, Goodnow CC. Illuminating autoimmune regulators through controlled variation of the mouse genome sequence.
Immunity 2004;20:669–679.
67. Kuroda N, et al. Development of autoimmunity against transcriptionally unrepressed
target antigen in the thymus of Aire-deficient
mice. J Immunol 2005;174:1862–1870.
68. Rubin GM, et al. Signal transduction downstream from Ras in Drosophila. Cold Spring
Harb Symp Quant Biol 1997;62:347–352.

69. Simon M, Bowtell D, Dodson G, Laverty T,
Rubin G. Ras1 and a putative guanine
nucleotide exchange factor perform crucial
steps in signaling by the sevenless protein
tyrosine kinase. Cell 1991;67:701–716.
70. Liston A, Lesage S, Gray D, Boyd R, Goodnow
CC. Genetic lesions in T-cell tolerance and
thresholds for autoimmunity. Immunol Rev
2005;204:87–101.
71. Akkaraju S, Ho WY, Leong D, Canaan K, Davis
MM, Goodnow CC. A range of CD4 T cell
tolerance: partial inactivation to organ-specific
antigen allows nondestructive thyroiditis or
insulitis. Immunity 1997;7:255–271.
72. Lesage S, Hartley SB, Akkaraju S, Wilson J,
Townsend M, Goodnow CC. Failure to censor
forbidden clones of CD4 T cells in autoimmune
diabetes. J Exp Med 2002;196:1175–1188.
73. Nelms KA, Goodnow CC. Genome-wide ENU
mutagenesis to reveal immune regulators.
Immunity 2001;15:409–418.

Immunological Reviews 210/2006

39

